Idorsia Ltd (CH:IDIA)
:IDIA
Want to see CH:IDIA full AI Analyst Report?
IDIA Stock Chart & Stats
CHF3.71
-CHF0.05(-3.98%)
At close: 4:00 PM EST
CHF3.71
-CHF0.05(-3.98%)
Day’s Range― - ―
52-Week RangeCHF1.80 - CHF4.87
Previous CloseN/A
Volume178.76K
Average Volume (3M)2.48M
Market Cap
CHF1.15B
Enterprise ValueCHF2.18B
Total Cash (Recent Filing)CHF94.70M
Total Debt (Recent Filing)CHF1.32B
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Jul 30, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding255,040,510
10 Day Avg. Volume2,649,008
30 Day Avg. Volume2,478,790
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-0.80
Price to Sales (P/S)4.14
P/FCF Ratio-5.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF4.75Price Target Upside28.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.56
Revenue Forecast (FY)CHF227.22M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~90% gross margins indicate durable product-level economics and strong pricing or low COGS for marketed assets. Over 2-6 months this supports resilience to sales volatility and gives room to absorb SG&A, licensing or R&D investment if commercial traction improves.
Commercialized Product (QUVIVIQ)Having an approved, marketed medicine provides recurring product-sale revenue and commercial infrastructure. QUVIVIQ's presence reduces binary development risk vs pure R&D companies and enables future royalty or partnership upside from geographic or label expansion.
Prior Revenue Scale-upThe firm has demonstrated the ability to scale revenue materially from earlier years, showing commercial execution and market demand potential. This track record suggests the organization can rebuild sales momentum if distribution, marketing or partnership investments resume.
Bears Say
Highly Stressed Balance SheetDeeply negative equity and debt far exceeding assets materially constrain financial flexibility, raising refinancing and covenant risk. Over the medium term this limits the company's ability to fund development or commercial expansion without dilutive equity or onerous financing.
Negative Cash Flow / Ongoing BurnPersistent operating and free cash flow deficits indicate the business consumes cash to operate and grow. Continued burn forces reliance on external funding, which is difficult with a stressed balance sheet, and increases execution risk for late-stage programs and commercialization.
Sharp Recent Revenue DeclineA steep TTM revenue drop coupled with large operating losses signals volatile demand or commercialization setbacks. Such revenue volatility makes planning and investment decisions harder and can impair the pathway to self-sustaining profitability absent structural recovery.
IDIA FAQ
What was Idorsia Ltd’s price range in the past 12 months?
Idorsia Ltd lowest stock price was CHF1.80 and its highest was CHF4.87 in the past 12 months.
What is Idorsia Ltd’s market cap?
Idorsia Ltd’s market cap is CHF1.15B.
When is Idorsia Ltd’s upcoming earnings report date?
Idorsia Ltd’s upcoming earnings report date is Jul 30, 2026 which is in 46 days.
How were Idorsia Ltd’s earnings last quarter?
Idorsia Ltd released its earnings results on Apr 28, 2026. The company reported -CHF0.16 earnings per share for the quarter, beating the consensus estimate of -CHF0.185 by CHF0.025.
Is Idorsia Ltd overvalued?
According to Wall Street analysts Idorsia Ltd’s price is currently Undervalued.
Does Idorsia Ltd pay dividends?
Idorsia Ltd pays a Notavailable dividend of CHF11.841 which represents an annual dividend yield of N/A. See more information on Idorsia Ltd dividends here
What is Idorsia Ltd’s EPS estimate?
Idorsia Ltd’s EPS estimate is -0.23.
How many shares outstanding does Idorsia Ltd have?
Idorsia Ltd has 255,040,510 shares outstanding.
What happened to Idorsia Ltd’s price movement after its last earnings report?
Idorsia Ltd reported an EPS of -CHF0.16 in its last earnings report, beating expectations of -CHF0.185. Following the earnings report the stock price went up 4.782%.
Which hedge fund is a major shareholder of Idorsia Ltd?
Currently, no hedge funds are holding shares in CH:IDIA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Idorsia Ltd
Idorsia Ltd is a biopharmaceutical company based in Switzerland, dedicated to the discovery, development, and commercialization of innovative medicines that address significant unmet medical needs. The company maintains a diverse clinical development pipeline, with therapeutic focuses spanning central nervous system (CNS), cardiovascular, and immunological disorders, as well as various orphan diseases. Idorsia engages in several strategic collaborations: A partnership with Janssen Biotech Inc. for the joint development and commercialization of aprocitentan and its related compounds or products. A licensing agreement with Mochida Pharmaceutical covers the supply, co-development, and co-marketing of daridorexant. The company collaborates with Hoffman-La Roche Inc. to develop and market compounds within the field of cancer immunotherapy. An alliance with Antares Pharma, Inc. focuses on the creation of a self-administered drug delivery system for Selatogrel. A partnership with Neurocrine Biosciences, Inc. is in place for the development and commercialization of ACT-709478, an epilepsy treatment currently in Phase II clinical trials. Idorsia Ltd was founded in 2017 and its corporate headquarters are situated in Allschwil, Switzerland.
IDIA Stock 12 Month Forecast
Average Price Target
CHF4.75
▲(28.03% Upside)
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Kuros Biosciences
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―
Options Prices
Currently, No data available
---